Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Mazen Animal Health Inc. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are distributed among 3 distinct examiners, meaning every pending matter is being reviewed by a different individual. This lack of examiner overlap suggests that prosecution strategies must be tailored to 3 different sets of examiner preferences. The portfolio is active across 2 distinct art units, showing some concentration of technical subject matter despite the variety of examiners.
BLUMEL, BENJAMIN P is the busiest examiner for the company, with 1 pending office action under their review. Since there are 3 distinct examiners for the actions, the workload is distributed across the group, and the busiest examiner designation is shared among all participants. Navigating 2 distinct art units while managing the pending office actions requires coordination across different pharmaceutical or biological examination groups. This structure ensures that the pending office actions are evaluated independently by the 3 distinct examiners involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BLUMEL, BENJAMIN P | 1 | 70.8% | +30.5% |
| CHATTERJEE, JAYANTA | 1 | 45.5% | +80.0% |
| BUCKMASTER, MARLENE VRENI | 1 | 25.8% | +78.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17805396 | ORAL ADMINISTRATION OF CORONAVIRUS SPIKE PROTEIN FOR ALTERING CYTOKINE LEVELS AND PROVIDING PASSIVE IMMUNITY TO NEWBORN PIGS | BUCKMASTER, MARLENE VRENI | 147d overdue |
| 18756402 | EXPRESSION OF EIMERIA SEQUENCES IN PLANTS AND PLANT PRODUCED VACCINE FOR SAME | CHATTERJEE, JAYANTA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17805396 | ORAL ADMINISTRATION OF CORONAVIRUS SPIKE PROTEIN FOR ALTERING CYTOKINE LEVELS AND PROVIDING PASSIVE IMMUNITY TO NEWBORN PIGS | BUCKMASTER, MARLENE VRENI | 147d overdue |
| 18989993 | METHODS FOR PROVIDING PROTECTION TO PORCINE EPIDEMIC DIARRHEA VIRUS (PEDV) WITH A PLANT PRODUCED VACCINE | BLUMEL, BENJAMIN P | — |
| 18756402 | EXPRESSION OF EIMERIA SEQUENCES IN PLANTS AND PLANT PRODUCED VACCINE FOR SAME | CHATTERJEE, JAYANTA | — |
| Art Unit | Apps |
|---|---|
| 1662 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18989993 | METHODS FOR PROVIDING PROTECTION TO PORCINE EPIDEMIC DIARRHEA VIRUS (PEDV) WITH A PLANT PRODUCED VACCINE | BLUMEL, BENJAMIN P | — | §102§112DP | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18756402 | EXPRESSION OF EIMERIA SEQUENCES IN PLANTS AND PLANT PRODUCED VACCINE FOR SAME | CHATTERJEE, JAYANTA | 1662 | §102§103§112 | Non-Final OA | — | Pending | Jun 27, 2024 |
| 17805396 | ORAL ADMINISTRATION OF CORONAVIRUS SPIKE PROTEIN FOR ALTERING CYTOKINE LEVELS AND PROVIDING PASSIVE IMMUNITY TO NEWBORN PIGS | BUCKMASTER, MARLENE VRENI | 1672 | §103§112Other | Final Rejection | 147d overdue | Pending | Jun 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial